Clinical outcomes according to molecular subtypes in stage II–III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. Issue 4 (21st November 2016)

• Record Type: Journal Article
• Authors: Kim, Hakyoung; Park, Won; Huh, Seung Jae; Choi, Doo Ho; Noh, Jae Myoung; Im, Young‐Hyuck; Ahn, Jin Seok; Park, Yeon Hee; Nam, Seok Jin; Kim, Seok Won; Lee, Jeong Eon; Cho, Eun Yoon
• Is Part Of: Asia-Pacific journal of clinical oncology. Volume 13:Issue 4(2017)
• Page Start: 329
• Page End: 336
• Publication Date: 2016-11-21
• Subjects: breast cancer -- molecular subtypes -- neo‐adjuvant chemotherapy -- radiotherapy; Oncology -- Pacific Area -- Periodicals; Cancer -- Treatment -- Pacific Area -- Periodicals; Cancer -- Pacific Area -- Periodicals; Cancer -- Treatment -- Periodicals; 616.9940095
• DOI: 10.1111/ajco.12652
• Languages: English
• ISSNs: 1743-7555

Abstract

Abstract: Aim: We evaluated the tumor response and clinical outcomes according to molecular subtypes in stage II–III breast cancer patients who received neo‐adjuvant chemotherapy (NAC) followed by surgery and radiotherapy. Methods: We retrospectively analyzed 329 patients with clinical stage II–III breast cancer who received NAC followed by surgery and radiotherapy. Luminal A and B, HER2‐enriched and triple‐negative subgroups were identified. Results: The overall pathologic complete response (pCR) rate after NAC was 20.1% and the HER2‐enriched subgroup had the highest pCR rate (43.6%), whereas luminal A showed the lowest rate of pCR (4.6%). The median follow‐up duration was 55 months (range, 5–98 months). The 5‐year overall survival (OS) and disease‐free survival (DFS) rates were 88.9% and 72.9%, respectively. In subgroup analysis, according to the pathologic response (pCR vs non‐pCR), the triple‐negative subtype exhibited a significant difference in 5‐year OS rate (100.0% vs 71.6%, P = 0.005) and 5‐year DFS rate (93.1% vs 55.1%, P < 0.001). A distinct survival difference according to molecular subtype was found, particularly in the non‐pCR group (5‐year OS and DFS, P < 0.001, respectively). Conclusions: The non‐pCR group showed significantly decreased 5‐year OS and DFS rates compared to the pCR group, especially in triple negative and HER2‐enriched breast cancer patients. A significant difference in survival rates and molecular subtypes was found in patients who failed to attain pCR.